

# Shi-Yong Sun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2450836/publications.pdf>

Version: 2024-02-01

175  
papers

17,719  
citations

28190

55  
h-index

13727

129  
g-index

182  
all docs

182  
docs citations

182  
times ranked

31215  
citing authors

#	ARTICLE	IF	CITATIONS
1	The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. <i>Pharmacological Research</i> , 2022, 175, 105998.	3.1	21
2	Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. <i>Oncogene</i> , 2022, 41, 1691-1700.	2.6	9
3	Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. <i>Neoplasia</i> , 2022, 29, 100798.	2.3	5
4	Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. <i>Cancer Gene Therapy</i> , 2022, 29, 1558-1569.	2.2	7
5	The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.. <i>American Journal of Cancer Research</i> , 2022, 12, 779-792.	1.4	0
6	mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?. <i>Frontiers of Medicine</i> , 2021, 15, 221-231.	1.5	34
7	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell "Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	0.5	93
8	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. <i>Theranostics</i> , 2021, 11, 3964-3980.	4.6	15
9	Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 1-10.	1.3	11
10	Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling. <i>Biomolecules</i> , 2021, 11, 499.	1.8	20
11	Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2021, 26, 338-347.	2.2	4
12	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 1622-1634.	1.5	19
13	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. <i>Cancer Research</i> , 2021, 81, 4822-4834.	0.4	29
14	Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer. <i>Acta Biomaterialia</i> , 2021, 129, 258-268.	4.1	18
15	Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. <i>Cell Reports Methods</i> , 2021, 1, 100050.	1.4	10
16	MET inhibition downregulates ADR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription. <i>Neoplasia</i> , 2021, 23, 766-774.	2.3	8
17	Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors. <i>Oncoscience</i> , 2021, 8, 80-81.	0.9	1
18	Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors. <i>Oncoscience</i> , 2021, 8, 101-102.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. <i>Cancer Letters</i> , 2021, 519, 141-149.	3.2	8
20	Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. <i>Oncogene</i> , 2021, 40, 6653-6665.	2.6	17
21	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor mutant non-small cell lung cancer cells to osimertinib. <i>Cancer</i> , 2020, 126, 1339-1350.	2.0	40
22	Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. <i>Translational Oncology</i> , 2020, 13, 100847.	1.7	20
23	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. <i>Lung Cancer</i> , 2020, 150, 26-35.	0.9	11
24	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor mutant lung cancers. <i>Cancer</i> , 2020, 126, 3788-3799.	2.0	26
25	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. <i>Cancer Research</i> , 2020, 80, 2380-2393.	0.4	28
26	A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer. <i>Theranostics</i> , 2020, 10, 3708-3721.	4.6	36
27	Overcoming acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. <i>Molecular Oncology</i> , 2020, 14, 882-895.	2.1	26
28	Overcoming acquired resistance of epidermal growth factor receptor mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). <i>Cancer</i> , 2020, 126, 2024-2033.	2.0	32
29	Does the natural product, honokiol, have value in the battle against osimertinib resistance?. <i>Oncoscience</i> , 2020, 7, 73-75.	0.9	0
30	The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. <i>American Journal of Cancer Research</i> , 2020, 10, 3316-3327.	1.4	2
31	Does the natural product, honokiol, have value in the battle against osimertinib resistance?. <i>Oncoscience</i> , 2020, 7, 73-75.	0.9	0
32	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced $\beta$ -TrCP degradation. <i>Oncogene</i> , 2019, 38, 6270-6282.	2.6	53
33	MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 63.	6.9	181
34	mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis. <i>Cancer Research</i> , 2019, 79, 3725-3736.	0.4	20
35	The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. <i>Translational Oncology</i> , 2019, 12, 705-713.	1.7	20
36	Tumour necrosis factor $\alpha$ -induced protein 8-like 2 is a novel regulator of proliferation, migration, and invasion in human rectal adenocarcinoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1698-1713.	1.6	18

#	ARTICLE	IF	CITATIONS
37	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. <i>PLoS ONE</i> , 2019, 14, e0206309.	1.1	7
38	Does osimertinib treatment discriminate young patients?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1852-S1854.	0.6	1
39	Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. <i>Oncogene</i> , 2018, 37, 3415-3425.	2.6	15
40	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 36-43.	0.9	11
41	Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. <i>Cancer Letters</i> , 2018, 435, 44-54.	3.2	23
42	Therapeutic potential of osimertinib in the treatment of lung cancer with HER2 aberrations. <i>Translational Cancer Research</i> , 2018, 7, S577-S579.	0.4	0
43	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017, 77, 3001-3012.	0.4	24
44	Inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by rapamycin. <i>Heliyon</i> , 2017, 3, e00378.	1.4	11
45	The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. <i>Scientific Reports</i> , 2017, 7, 8027.	1.6	25
46	Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. <i>Clinical Cancer Research</i> , 2017, 23, 6567-6579.	3.2	103
47	DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion. <i>Cell Communication and Signaling</i> , 2017, 15, 18.	2.7	8
48	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 111.	1.8	78
49	Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. <i>European Journal of Cancer</i> , 2016, 65, 21-32.	1.3	25
50	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. <i>Cancer Letters</i> , 2016, 380, 494-504.	3.2	137
51	Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. <i>Journal of Biological Chemistry</i> , 2016, 291, 21694-21702.	1.6	22
52	Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. <i>Scientific Reports</i> , 2016, 6, 26803.	1.6	14
53	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
54	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. <i>Oncotarget</i> , 2015, 6, 8974-8987.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. <i>Cancer Letters</i> , 2015, 364, 70-78.	3.2	40
56	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1859-1868.	3.2	22
57	Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. <i>Chemistry and Biology</i> , 2015, 22, 957-964.	6.2	6
58	Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. <i>Journal of Biological Chemistry</i> , 2015, 290, 14120-14129.	1.6	59
59	mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. <i>Molecular and Cellular Biology</i> , 2015, 35, 2344-2355.	1.1	48
60	Cables1 Complex Couples Survival Signaling to the Cell Death Machinery. <i>Cancer Research</i> , 2015, 75, 147-158.	0.4	35
61	The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. <i>Oncotarget</i> , 2015, 6, 17532-17542.	0.8	38
62	The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. <i>Oncotarget</i> , 2015, 6, 34669-34679.	0.8	35
63	Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. <i>Oncotarget</i> , 2015, 6, 41324-41338.	0.8	28
64	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2014, 120, 3940-3951.	2.0	53
65	Poly (ADP-ribose) polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <i>Cancer Medicine</i> , 2014, 3, 1579-1594.	1.3	74
66	Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth. <i>Cancer Research</i> , 2014, 74, 2555-2568.	0.4	40
67	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. <i>Blood</i> , 2014, 123, 3269-3276.	0.6	64
68	c-FLIP links mTORC2 to apoptosis. <i>Oncoscience</i> , 2014, 1, 306-307.	0.9	2
69	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. <i>Cancer</i> , 2013, 119, 1503-1511.	2.0	14
70	mTOR kinase inhibitors as potential cancer therapeutic drugs. <i>Cancer Letters</i> , 2013, 340, 1-8.	3.2	128
71	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer. <i>Cancer Research</i> , 2013, 73, 5485-5496.	0.4	62
72	The E3 ubiquitin ligases $\hat{1}$ -TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. <i>Molecular Cancer</i> , 2013, 12, 146.	7.9	58

#	ARTICLE	IF	CITATIONS
73	The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. <i>Cancer Letters</i> , 2013, 338, 229-238.	3.2	28
74	Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2. <i>Science Signaling</i> , 2013, 6, ra55.	1.6	23
75	mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis. <i>Cancer Research</i> , 2013, 73, 1946-1957.	0.4	36
76	Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation. <i>Journal of Biological Chemistry</i> , 2013, 288, 13215-13224.	1.6	47
77	Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2200-2212.	1.9	137
78	Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2013, 14, 365-369.	1.5	19
79	Impact of genetic alterations on mTOR-targeted cancer therapy. <i>Chinese Journal of Cancer</i> , 2013, 32, 270-274.	4.9	8
80	Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 45-56.	1.9	40
81	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 272-280.	1.5	52
82	Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases. <i>Journal of Biological Chemistry</i> , 2012, 287, 6113-6127.	1.6	11
83	Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 257-267.	1.6	35
84	Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma. <i>Oncology Reports</i> , 2012, 28, 659-667.	1.2	22
85	The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition. <i>Cancer Prevention Research</i> , 2012, 5, 612-620.	0.7	15
86	NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC <sup>1</sup> /FAK loop. <i>Cancer Letters</i> , 2012, 318, 106-113.	3.2	53
87	K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. <i>Cancer Letters</i> , 2012, 322, 58-69.	3.2	24
88	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
89	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. <i>Cancer Letters</i> , 2012, 325, 139-146.	3.2	54
90	c-Myc Suppression of DNA Double-strand Break Repair. <i>Neoplasia</i> , 2012, 14, 1190-IN35.	2.3	48

#	ARTICLE	IF	CITATIONS
91	Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression. <i>Cancer Research</i> , 2011, 71, 5245-5254.	0.4	41
92	The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. <i>PLoS ONE</i> , 2011, 6, e20899.	1.1	64
93	The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2415-2425.	1.9	40
94	Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3. <i>Cancer Research</i> , 2011, 71, 6270-6281.	0.4	35
95	Pleiotropic functions of EAPII/TTRAP/TDP2. <i>Cell Cycle</i> , 2011, 10, 3274-3283.	1.3	25
96	Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response. <i>Clinical Cancer Research</i> , 2011, 17, 3181-3192.	3.2	38
97	Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1460-1469.	1.9	90
98	Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 902-914.	1.9	64
99	Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. <i>Cancer Biology and Therapy</i> , 2011, 12, 549-555.	1.5	56
100	Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis. <i>Molecular and Cellular Pharmacology</i> , 2011, 3, 31-34.	1.7	27
101	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. <i>Blood</i> , 2010, 116, 5285-5288.	0.6	25
102	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 3903-3909.	2.0	36
103	Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax. <i>PLoS ONE</i> , 2010, 5, e13393.	1.1	28
104	Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent $\beta$ -Tubulin Degradation. <i>Journal of Biological Chemistry</i> , 2010, 285, 16096-16104.	1.6	91
105	ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1. <i>Journal of Biological Chemistry</i> , 2010, 285, 41310-41319.	1.6	56
106	Enhancing perifosine's anticancer efficacy by preventing autophagy. <i>Autophagy</i> , 2010, 6, 184-185.	4.3	24
107	N-acetylcysteine, reactive oxygen species and beyond. <i>Cancer Biology and Therapy</i> , 2010, 9, 109-110.	1.5	225
108	The eIF4E/eIF4G Interaction Inhibitor 4EGI-1 Augments TRAIL-Mediated Apoptosis through c-FLIP Down-regulation and DR5 Induction Independent of Inhibition of Cap-Dependent Protein Translation. <i>Neoplasia</i> , 2010, 12, 346-IN7.	2.3	81

#	ARTICLE	IF	CITATIONS
109	Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. <i>Molecular Cancer</i> , 2010, 9, 23.	7.9	25
110	c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. <i>Molecular Cancer</i> , 2010, 9, 315.	7.9	29
111	Protein Phosphatase 2A Negatively Regulates Eukaryotic Initiation Factor 4E Phosphorylation and eIF4F Assembly through Direct Dephosphorylation of Mnk and eIF4E. <i>Neoplasia</i> , 2010, 12, 848-855.	2.3	69
112	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 1165-1177.	3.9	133
113	c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589. <i>PLoS ONE</i> , 2010, 5, e10376.	1.1	46
114	Analysis of Death Receptor 5 and Caspase-8 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma and Their Prognostic Impact. <i>PLoS ONE</i> , 2010, 5, e12178.	1.1	41
115	Enhancing mTOR-targeted cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1193-1203.	1.5	56
116	The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. <i>Journal of Biological Chemistry</i> , 2009, 284, 23225-23233.	1.6	103
117	Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. <i>Cancer Biology and Therapy</i> , 2009, 8, 1463-1469.	1.5	97
118	Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2575-2585.	1.9	14
119	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy. <i>Cancer Research</i> , 2009, 69, 8967-8976.	0.4	137
120	The Role of Cetuximab in the Management of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 230-238.	1.1	11
121	Inhibition of I $\kappa$ B Kinase-Nuclear Factor- $\kappa$ B Signaling Pathway by 3,5-Bis(2-fluorobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin. <i>Molecular Pharmacology</i> , 2008, 74, 654-661.	1.0	151
122	2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 809-817.	1.9	79
123	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. <i>Cancer Biology and Therapy</i> , 2008, 7, 1952-1958.	1.5	86
124	Therapeutic potential of synthetic triterpenoids in neuroblastoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 718-720.	1.5	1
125	Down-regulation of 14-3-3 $\sigma$ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 162-167.	3.3	137
126	Coupling of Endoplasmic Reticulum Stress to CDDO-Me-Induced Up-regulation of Death Receptor 5 via a CHOP-Dependent Mechanism Involving JNK Activation. <i>Cancer Research</i> , 2008, 68, 7484-7492.	0.4	109



#	ARTICLE	IF	CITATIONS
127	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2212-2223.	1.9	47
128	LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins. <i>Cancer Research</i> , 2008, 68, 7270-7277.	0.4	68
129	Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. <i>Cancer Research</i> , 2008, 68, 7409-7418.	0.4	152
130	Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors. <i>Clinical Cancer Research</i> , 2008, 14, 5090-5098.	3.2	38
131	CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5335-5344.	0.4	44
132	Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3556-3565.	1.9	48
133	Modulation of death receptors by cancer therapeutic agents. <i>Cancer Biology and Therapy</i> , 2008, 7, 163-173.	1.5	102
134	Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation. <i>Molecular and Cellular Biology</i> , 2007, 27, 7405-7413.	1.1	137
135	Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 749-754.	1.5	8
136	PPAR $\beta$ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 99-106.	1.5	53
137	c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 1614-1620.	1.5	48
138	CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2007, 72, 1269-1279.	1.0	45
139	The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells. <i>Cancer Research</i> , 2007, 67, 4973-4980.	0.4	14
140	The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 18800-18809.	1.6	49
141	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2029-2038.	1.9	87
142	The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells. <i>Cancer Research</i> , 2007, 67, 4981-4988.	0.4	150
143	Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. <i>Nature Cell Biology</i> , 2007, 9, 1199-1207.	4.6	82
144	Depletion of intracellular Glutathione Contributes to JNK-Mediated Death Receptor 5 Upregulation and Apoptosis Induction by the Novel Synthetic Triterpenoid Methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). <i>Cancer Biology and Therapy</i> , 2006, 5, 492-497.	1.5	54

#	ARTICLE	IF	CITATIONS
145	Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2006, 12, 273-280.	3.2	96
146	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. <i>Cancer Research</i> , 2006, 66, 11115-11119.	0.4	69
147	Targeting mTOR signaling for lung cancer therapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 109-11.	0.5	9
148	Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model. <i>Clinical Cancer Research</i> , 2005, 11, 6261-6269.	3.2	123
149	Activation of Nuclear Factor- $\kappa$ B Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells. <i>Cancer Research</i> , 2005, 65, 6354-6363.	0.4	79
150	Decoy Receptor 2 (DcR2) Is a p53 Target Gene and Regulates Chemosensitivity. <i>Cancer Research</i> , 2005, 65, 9169-9175.	0.4	73
151	Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. <i>Cancer Biology and Therapy</i> , 2005, 4, 413-419.	1.5	30
152	Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. <i>Cancer Research</i> , 2005, 65, 7052-7058.	0.4	759
153	c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oate in Human Lung Cancer Cells. <i>Cancer Research</i> , 2004, 64, 7570-7578.	0.4	161
154	The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. <i>Cancer Biology and Therapy</i> , 2004, 3, 1092-1098.	1.5	27
155	Retinoic Acid Receptor Beta and Colon Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 87-88.	1.5	11
156	Apoptosis as a Novel Target for Cancer Chemoprevention. <i>Journal of the National Cancer Institute</i> , 2004, 96, 662-672.	3.0	463
157	Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1769-1780.	3.0	240
158	p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site. <i>Cancer Research</i> , 2004, 64, 5078-5083.	0.4	158
159	Combination of Farnesyl Transferase Inhibition (Lonafarnib) and Proteasome Inhibition (Bortezomib) Results in Rapid Caspase Activation and down Regulation of p-AKT in Myeloma cell Lines and Primary Myeloma Cells.. <i>Blood</i> , 2004, 104, 2471-2471.	0.6	1
160	Hypermethylation of the Death-Associated Protein Kinase Promoter Attenuates the Sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Non- $\mu$ Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2004, 2, 685-691.	1.5	28
161	Recent developments of retinoids as therapeutic agents. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 529-542.	2.4	4
162	How Much Do We Know About Retinoid-Regulated Genes?. <i>Cancer Biology and Therapy</i> , 2002, 1, 28-30.	1.5	4

#	ARTICLE	IF	CITATIONS
163	Retinoids and their receptors in cancer development and chemoprevention. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 41-55.	2.0	293
164	Evidence that the human death receptor 4 is regulated by activator protein 1. <i>Oncogene</i> , 2002, 21, 3121-3129.	2.6	70
165	The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. <i>Cancer Research</i> , 2002, 62, 2430-6.	0.4	67
166	Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 177-84.	1.9	45
167	Overexpression of Bcl2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 788-797.	1.0	125
168	Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. <i>Journal of Cellular Physiology</i> , 2001, 188, 98-105.	2.0	126
169	All-trans-retinoic Acid Enhances the Effect of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Head and Neck Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2001, 111, 1459-1464.	1.1	4
170	Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. <i>Oncogene</i> , 2000, 19, 4513-4522.	2.6	63
171	Dual Mechanisms of Action of the Retinoid CD437: Nuclear Retinoic Acid Receptor-Mediated Suppression of Squamous Differentiation and Receptor-Independent Induction of Apoptosis in UMSCC22B Human Head and Neck Squamous Cell Carcinoma Cells. <i>Molecular Pharmacology</i> , 2000, 58, 508-514.	1.0	51
172	Evidence That Retinoic Acid Receptor $\beta$ Induction by Retinoids Is Important for Tumor Cell Growth Inhibition. <i>Journal of Biological Chemistry</i> , 2000, 275, 17149-17153.	1.6	94
173	Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. <i>Oncogene</i> , 1999, 18, 2357-2365.	2.6	110
174	Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. <i>Oncogene</i> , 1999, 18, 3894-3901.	2.6	31
175	Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. , 1997, 173, 279-284.		63